We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Case report and brief literature review: possible association of secukinumab with Guillain-Barre' syndrome in psoriasis.
- Authors
Gang Liang; Yongmei Han; Haiyan He; Ci Lu; Chen Zhu
- Abstract
The etiology of Guillain-Barre' syndrome (GBS) may be autoimmune. About twothirds of patients typically experience their first symptoms within 5 days to 3 weeks after common infectious diseases, surgery, or vaccination. Infection is a triggering factor for over 50% of patients. In recent years, a growing number of studies have indicated that some immune checkpoint inhibitors and COVID-19 may also contribute to the occurrence of GBS. However, drugs are considered a rare cause of GBS. The patient in our case was a 70-year-old man who developed GBS after initiating secukinumab for psoriasis. Upon diagnosis suggesting a potential association between secukinumab and the development of GBS, as per the Naranjo adverse drug reaction (ADR) probability scale, we decided to discontinue the drug. Following this intervention, along with the administration of immunoglobulin, the patient exhibited a significant improvement in extremity weakness. The association of GBS with secukinumab treatment, as observed in this case, appears to be uncommon. The underlying mechanisms that may link secukinumab to the development of GBS are not yet fully understood and warrant further scientific inquiry and rigorous investigation. However, we hope that this report can raise greater awareness and vigilance among medical professionals to enhance the safety of patients' medication.
- Subjects
LITERATURE reviews; GUILLAIN-Barre syndrome; DRUG side effects; CONSCIOUSNESS raising; IMMUNE checkpoint inhibitors
- Publication
Frontiers in Immunology, 2024, p1
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2024.1412470